Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease

Timothy B. Niewold, Deborah Alpert, Carla R. Scanzello, Stephen A. Paget

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Thrombotic thrombocytopenic purpura (TTP) causes significant morbidity and mortality, and may be associated with connective tissue diseases (CTD). Some cases are refractory to plasma exchange and require immunosuppressive therapy. We describe 2 patients with CTD who had refractory TTP treated successfully with rituximab. Both patients also developed heparin-induced thrombocytopenia (HIT). The propensity of a patient with a CTD to develop autoantibodies to ADAMTS-13 and platelets likely explains the association of such a disease with TTP and HIT. Rituximab should be considered in this complex clinical setting, because it may decrease the production of multiple pathogenic autoantibodies.

Original languageEnglish (US)
Pages (from-to)1194-1196
Number of pages3
JournalJournal of Rheumatology
Volume33
Issue number6
StatePublished - Jun 1 2006

Keywords

  • Connective tissue diseases
  • Heparin
  • Monoclonal antibodies
  • Systemic lupus erythematosus
  • Thrombocytopenia
  • Thrombotic thromobocytopenic purpura

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease'. Together they form a unique fingerprint.

Cite this